At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 14 enrolled
Drug / intervention
Stiolto Respimat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Crossover, Placebo Controlled, Double-blind Trial of the Effect of STIOLTO™ RESPIMAT® on Central and Peripheral Components of Fatigue During Exercise in Chronic Obstructive Pulmonary Disease
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·interventional·Posted Jul 27, 2016·Updated Aug 6, 2020
In Brief
A Phase 4 clinical trial evaluating Stiolto Respimat and Placebo Respimat for Chronic Obstructive Pulmonary Disease. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether exercise can be prolonged in COPD can by the inhaled bronchodilator Stiolto Respimat. The study will identify whether any endurance benefit is due to reduction in fatigue that originates within the skeletal muscles and/or from effects on neural activation of the skeletal muscles.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesUnited States
CollaboratorsBoehringer Ingelheim
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartMar 2017
Primary CompletionAug 2018
TodayJul 2026
First PostedJul 27, 2016
Enrollment StartMar 1, 2017
Primary CompletionAug 6, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.9 years ago
Interventions
Stiolto Respimatdrug
Oral inhalation spray
Placebo Respimatdrug
Oral inhalation spray